Corsera Health Begins Phase 1 Trial of RNA-Based Treatment to Prevent Cardiovascular Disease

0
4
Rena N. Denoncourt

BOSTON–Corsera Health has initiated a Phase 1 clinical trial in Australia and New Zealand to evaluate two experimental RNA-based therapies designed to lower cholesterol and blood pressure, marking the company’s first clinical study of a dual-targeting approach to cardiovascular disease prevention.

The Boston-based clinical-stage company is developing COR-1004 and COR-2003 as components of a potential once-yearly injectable treatment intended to address two major risk factors for cardiovascular disease: elevated LDL cholesterol and high blood pressure.

The new trial will evaluate COR-2003 independently and in combination with COR-1004 to assess their safety, tolerability, and biological activity.

Both treatments use small interfering RNA (siRNA) technology, which reduces the production of specific proteins by targeting the genetic instructions responsible for their synthesis.

COR-1004 targets PCSK9, a protein involved in regulating LDL cholesterol levels. The experimental treatment has already demonstrated initial clinical proof of concept in a separate ongoing Phase 1 trial, according to the company.

COR-2003 targets angiotensinogen (AGT), a protein involved in regulating blood pressure.

By combining the two therapies, Corsera aims to develop a preventive treatment that simultaneously lowers LDL cholesterol and blood pressure through a single annual subcutaneous injection.

“With COR-2003 now in the clinic, we aim to address the two key drivers of cardiovascular disease – LDL cholesterol and blood pressure – together in a single, once-annual preventive RNAi medicine,” said Rena N. Denoncourt, Chief Operating Officer of Corsera Health.

“We are highly encouraged by the data from the ongoing COR-1004 Phase 1 trial, which showed positive results across tolerability, safety, efficacy and durability that are consistent with a medicine intended for broad preventive use.”

The Phase 1 study is a randomized, double-blind, placebo-controlled trial involving healthy adult volunteers.

It consists of two parts designed to evaluate the individual and combined effects of the investigational therapies.

The first portion will examine increasing doses of COR-2003 administered alone, with researchers assessing safety and tolerability 90 days after treatment.

Secondary measurements will include how the drug behaves in the body, its ability to reduce angiotensinogen production, and its effect on blood pressure.

The second portion will evaluate the simultaneous administration of COR-1004 and COR-2003.

Researchers will assess safety and tolerability while measuring changes in PCSK9 activity, LDL cholesterol levels, angiotensinogen production, and blood pressure.

Participants will be monitored for 12 months to evaluate the treatments’ effects over time.

Corsera expects to report initial proof-of-concept results from patients receiving COR-2003 alone in early 2027.

Initial findings from the combination treatment groups are expected in mid-2027.

If development proceeds as planned, the company intends to begin a Phase 2 clinical trial of the dual-targeting preventive treatment by the end of 2027.

The company’s approach focuses on reducing long-term exposure to elevated cholesterol and blood pressure, both of which contribute to the development of cardiovascular disease.

Although medications are available to manage these risk factors, Corsera is investigating whether RNA interference technology could provide sustained reductions with less frequent dosing.

The proposed once-yearly treatment schedule remains an objective of the development program and has not yet been established through clinical testing.

In addition to its RNA-based drug development programs, Corsera is developing Klotho, an artificial intelligence-powered tool intended to estimate lifetime cardiovascular disease risk.

The technology is designed to help predict the potential benefits of lowering LDL cholesterol and blood pressure, supporting the company’s broader emphasis on disease prediction and prevention.

Corsera said its long-term strategy is to combine predictive technology with preventive medicines to reduce the burden of cardiovascular disease and extend the number of years people live in good health.

COR-1004 and COR-2003 remain investigational therapies, and their safety and effectiveness for preventing cardiovascular disease have not been established.

Leave A Reply

Please enter your comment!
Please enter your name here